- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01023815
Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (EVIDENCE)
Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Ancona, Italia, 60100
- Novartis Investigative Site
-
Bologna, Italia
- Novartis Investigative Site
-
Brescia, Italia
- Novartis Investigative Site
-
Cagliari, Italia
- Novartis Investigative Site
-
Catania, Italia
- Novartis Investigative Site
-
Coppito, Italia
- Novartis Investigative Site
-
Firenze, Italia
- Novartis Investigative Site
-
Genova, Italia, 16132
- Novartis Investigative Site
-
Milano, Italia, 20122
- Novartis Investigative Site
-
Modena, Italia, 41100
- Novartis Investigative Site
-
Napoli, Italia
- Novartis Investigative Site
-
Novara, Italia, 28100
- Novartis Investigative Site
-
Padova, Italia
- Novartis Investigative Site
-
Palermo, Italia
- Novartis Investigative Site
-
Parma, Italia
- Novartis Investigative Site
-
Perugia, Italia, 06070
- Novartis Investigative Site
-
Pisa, Italia
- Novarits Investigative Site
-
Roma, Italia
- Novartis Investigative Site
-
Rome, Italia
- Novartis Investigative Site
-
Salerno, Italia
- Novartis Investigative Site
-
Sassari, Italia, 07100
- Novartis Investigative Site
-
Siena, Italia, 53100
- Novartis Investigative Site
-
Torino, Italia, 10126
- Novartis Investigative Site
-
Treviso, Italia
- Novartis Investigative Site
-
Udine, Italia
- Novartis InvestigativeSite
-
Varese, Italia
- Novartis Investigative Site
-
Verona, Italia
- Novartis Investigative Site
-
Vicenza, Italia
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- recipients of 1st or 2nd single kidney transplant
- donor age >14 years
- females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline (Visit 2), and are required to practice an approved method of birth control for the duration of the study and for a period of 2 months following discontinuation of study medication
- patientswho are willing and able to participate in the study and from whom written informed consent has been obtained
Exclusion criteria:
Exclusion criteria at screening (pre-transplantation, Visit 1):
- recipients of kidney-pancreas transplant, double kidney or any other transplant
- recipients of a 2nd kidney transplant who lost the 1st for immunological reasons
- focal segmental glomerulosclerosis (FSGS), primary oxaluria or other diseases (as cause of end stage renal failure - ESRF) at high risk of rapid recurrence or requiring continuous corticosteroid treatment
- recipients of A-B-O incompatible transplants
- historical or current peak PRA of >25% (current = 3 months)
- patients with already existing antibodies against the donor
- thrombocytopenia (platelets <75,000/mm³), absolute neutrophil count of <1,500/mm³, leucopenia (leucocytes <2,500/mm³), or hemoglobin <6 g/dL
- symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, or to comply with the study requirements, or to give informed consent
- history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
- patients who are HIV positive or Hepatitis B surface antigen positive (HbsAg); HCV positive patients receiving interferon and/or ribavirin
- evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin >3 times UNL)
- evidence of drug or alcohol abuse
- body mass index (BMI) >35
- patients who need to be treated with drugs known to strongly interact with CsA and/or everolimus (as detailed in Appendix 2 of the protocol) should be excluded, if according the investigator this interferes with the objectives of the study
- women of child-bearing potential, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method
- pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/mL)
- use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
- history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
- patients with severe active infections or any other medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)
Additional exclusion criteria post-transplantation (Visit 2):
• graft not perfused or with thrombosis of the main vessels, according to angioscintigraphy or echocolordoppler within 48 hours after the end of surgical procedure
To avoid any possible influence of the confounding factors on the results of this study additional exclusion criteria at randomization were (Visit 5, Month 3):
- unsatisfactory renal function (CrCl according Cockcroft and Gault<40 mL/min)
- proteinuria ≥0.8 g/24 hrs
- steroid-resistant, humoral, moderate/severe (BANFF grade ≥II) biopsy proven acute rejections
- multiple (2 or more) biopsy proven or treated acute rejections or acute rejections leading to relevant loss of renal function
- acute rejection or impairment of renal function (increase of serum creatinine>30%) in the month preceding randomization
- severe/uncontrollable adverse events with suspected relationship to everolimus (e.g. anemia, oral aphtosis, arthralgia) for the control of which the investigator has planned the withdrawal of everolimus
- severe infections requiring hospitalization in the two weeks preceding randomization
poor compliance to prescribed treatments
- Other protocol-defined inclusion/exclusion criteria may apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Group A -Once-a-day regimen
Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12. Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL. Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning. |
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Otros nombres:
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day.
CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg.
Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Otros nombres:
continuous steroids
|
Experimental: Group B - Steroid Withdrawal group
Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12. Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks. |
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Otros nombres:
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day.
CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg.
Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Otros nombres:
continuous steroids
|
Comparador activo: Group C - Standard twice-a-day group
Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12. Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12. Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning. |
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Otros nombres:
Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day.
CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg.
Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Otros nombres:
continuous steroids
|
Experimental: Not Randomized Population (NRP)
NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90.
This group was addressed as "not randomized patients" (NRP) and described with respect to baseline characteristics, treatment and outcome variables.
|
Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.
Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Treatment Failure Rate
Periodo de tiempo: Between randomization (Month 3) and Month 12
|
Occurrence or not of treatment failure in each patient.
Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9).
|
Between randomization (Month 3) and Month 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12
Periodo de tiempo: Month 3 to Month 12
|
eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority
|
Month 3 to Month 12
|
Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12
Periodo de tiempo: Month 3 to Month 12
|
Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group). BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update. |
Month 3 to Month 12
|
Number of Participants With Graft and Patient Survival After Randomization
Periodo de tiempo: Month 3 to Month 12
|
Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death. Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up. |
Month 3 to Month 12
|
Change in Estimated Creatine Clearance
Periodo de tiempo: M3, M12
|
At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function.
The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula.
|
M3, M12
|
Change in Serum Creatinine
Periodo de tiempo: M3, M12
|
Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism.
Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function.
|
M3, M12
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes dermatológicos
- Agentes antifúngicos
- Inhibidores de calcineurina
- Everolimus
- Ciclosporina
- Ciclosporinas
Otros números de identificación del estudio
- CRAD001AIT12
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Trasplante Renal
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and Kidney... y otros colaboradoresReclutamientoEnfermedades Renales Crónicas | Fallo renal agudo | Lesión renal aguda | Insuficiencia Renal Aguda | Insuficiencia renal cronica | Insuficiencia Renal, Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia renal aguda | Insuficiencia Renal Crónica | Enfermedades... y otras condicionesEstados Unidos
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillTerminadoEnfermedades Renales Crónicas | Enfermedad Renal Crónica Etapa 5 | Enfermedad Renal Crónica etapa 4 | Enfermedad renal pediátrica | Enfermedad Renal Crónica etapa 3 | Enfermedad Renal Crónica Etapa V | Enfermedad renal crónica, estadio IV (grave) | Enfermedad Renal Crónica Etapa 2 | Enfermedad Renal...Estados Unidos
-
University Hospital, BordeauxMinistry of Health, FranceTerminadoTrasplante Renal | Enfermedad renal crónica en etapa terminal | Insuficiencia Renal Aguda SeveraFrancia
-
Wake Forest University Health SciencesStanford UniversityTerminadoTrasplante Renal | Rechazo Renal Agudo | Rechazo Renal Crónico | Rechazo de Trasplante Renal | Sistema Renina-AngiotensinaEstados Unidos
-
Faculdade de Ciências Médicas da Santa Casa de...TerminadoEnfermedad Renal Crónica | Diálisis renalBrasil
-
Outset MedicalTerminadoLesión renal aguda | Enfermedad renal en etapa terminal (ESRD) | Enfermedad renal en etapa terminal en diálisisEstados Unidos
-
Novartis PharmaceuticalsTerminadoHemodiálisis | Terapia de reemplazo renal | Enfermedad renal en etapa terminal (ESRD) | Trasplante Renal | Enfermedad renal crónica (ERC)Alemania, Estados Unidos, Bélgica, Italia, España, Croacia, Taiwán, Australia, Austria, Grecia, Corea, república de, Líbano, Chequia, Israel, Países Bajos, Eslovenia, Suiza, Tailandia, Noruega, Pavo, Suecia, Argentina, Brasil, Japón, Serbia, Federación Rusa y más
-
ArdelyxAstraZenecaTerminadoEnfermedad renal en etapa terminal | ESRD | Enfermedad Renal Crónica Etapa 5Estados Unidos
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)TerminadoFallo renal agudo | Insuficiencia renal cronicaAustria
-
Angiodynamics, Inc.TerminadoEnfermedad Renal Crónica | Lesión renal aguda | Fallo renal agudo | Insuficiencia renal crónica inducida por contrasteEstados Unidos
Ensayos clínicos sobre everolimus
-
Novartis PharmaceuticalsTerminadoLinfangioleiomiomatosis (LAM) | Complejo de esclerosis tuberosa (TSC)Estados Unidos, Reino Unido, Alemania, Italia, Federación Rusa, Países Bajos, Japón, Canadá, Polonia, Francia, España
-
Novartis PharmaceuticalsTerminadoCarcinoma hepatocelularHong Kong, Taiwán, Tailandia
-
The Netherlands Cancer InstituteActivo, no reclutandoCarcinomas neuroendocrinosPaíses Bajos
-
German Breast GroupNovartisTerminadoCáncer de mama metastásicoAlemania
-
Novartis PharmaceuticalsTerminadoTumor neuroendocrino gastroenteropancreático del sistema pulmonar o gastroenteropancreáticoAlemania
-
University of LuebeckTerminadoEnfermedad de la arteria coronariaAlemania
-
Guangdong Provincial People's HospitalNovartisDesconocidoTumores neuroendocrinos | Tumor carcinoidePorcelana
-
Centre Leon BerardSuspendido
-
Novartis PharmaceuticalsTerminadoCarcinoma De Célula RenalAustralia, Corea, república de
-
Asan Medical CenterTerminadoNeoplasia de estómagoCorea, república de